Actual Medicinal Product (AMP) Kivexa 600mg/300mg tablets (Originalis B.V.)

Stability Information

(Some stability information inherited from generic)

Stability: There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Notes: Store in an airtight container.
Provenance: This compatibility recommendation is derived from Kivexa 600mg/300mg tablets (ViiV Healthcare UK Ltd).
Generic: Abacavir + Lamivudine
Formulation: Abacavir 600mg / Lamivudine 300mg tablets

Abacavir + Lamivudine
- Abacavir 600mg / Lamivudine 300mg tablets
  - Kivexa 600mg/300mg tablets (Originalis B.V.)